10x Genomics partners with Cleveland Clinic on bladder cancer research

0 min read Updated on 17 Jun 2026, 07:17 PM

Reviewed by

Riya DScanX News Team

AI Summary

10x Genomics Inc partners with Cleveland Clinic to advance research in novel diagnostics for bladder cancer, integrating clinical care with research and education.

*this image is generated using AI for illustrative purposes only.

10x Genomics Inc has entered a research collaboration with Cleveland Clinic to advance research in novel diagnostics for bladder cancer. The partnership leverages Cleveland Clinic's integration of clinical care with research and education to drive innovation in diagnostics.

Collaboration Details

The collaboration focuses on developing novel diagnostics for bladder cancer, combining 10x Genomics' life science technology with Cleveland Clinic's clinical and research expertise. The initiative aims to improve diagnostic accuracy and patient outcomes.

Key Objectives

Advance research in bladder cancer diagnostics
Integrate clinical care with research and education
Leverage 10x Genomics' technology platform

About the Partners

Partner	Description
10x Genomics Inc	Life science technology leader focused on accelerating science and advancing human health
Cleveland Clinic	Nonprofit multispecialty academic medical center integrating clinical care with research and education

What is the expected timeline for the development and potential commercialization of these novel bladder cancer diagnostics?

How might this partnership influence 10x Genomics' revenue streams and market position in the life science technology sector?

Could this collaboration serve as a blueprint for future partnerships between 10x Genomics and other medical institutions?

Read Next Article

10x Genomics acquires Proteintech Genomics division

0 min read Updated on 09 Jun 2026, 09:54 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

AI Summary

10x Genomics has acquired Proteintech Genomics, a division of Proteintech Group, to bolster its high-plex proteomic solutions for single cell and spatial applications. The financial terms of the deal were not disclosed, and the transaction is not expected to significantly affect 10x Genomics' near-term financial outlook.

*this image is generated using AI for illustrative purposes only.

10x Genomics has acquired Proteintech Genomics, a division within Proteintech Group, to expand its capabilities in high-plex proteomic solutions for single cell and spatial applications on 10x platforms. The move aims to enhance the company's life science technology offerings, focusing on accelerating scientific research and advancing human health.

The financial terms of the transaction were not disclosed. 10x Genomics stated that the acquisition will not meaningfully impact its near-term financial outlook. Proteintech Group specializes in developing proteomic solutions, and this acquisition aligns with 10x Genomics' strategy to strengthen its product portfolio.

Key Details of the Acquisition

Aspect	Details
Acquiring Company	10x Genomics, Inc
Acquired Division	Proteintech Genomics
Parent Company	Proteintech Group
Specialization	High-plex proteomic solutions for single cell and spatial applications
Financial Terms	Undisclosed
Near-term Financial Impact	Not meaningful

The acquisition underscores 10x Genomics' commitment to innovation in the life sciences sector. By integrating Proteintech Genomics' expertise, the company expects to deliver more comprehensive solutions to its customers.

How will this acquisition influence 10x Genomics' competitive positioning in the single-cell and spatial analysis market?

What are the expected long-term revenue synergies from integrating Proteintech Genomics' solutions into 10x's platform?

Will 10x Genomics pursue further acquisitions to expand its life sciences technology portfolio?